期刊文献+

NAs治疗慢性乙型肝炎后HBsAg变化的特点和影响因素分析 被引量:2

Analysis of the characteristics and influencing factors of HBsAg change in chronic hepatitis B patients treated with NAs
下载PDF
导出
摘要 目的:观察慢性乙型病毒性肝炎(CHB)病人接受核苷(酸)类似物(NAs)治疗HBVDNA阴转后血清HBsAg定量的动态变化,对HBeAg阳性和HBeAg阴性组病人HBsAg定量的变化进行比较,推算HBsAg清除所需时间,探讨NAs药物治疗CHB的可能疗程。方法:以NAs治疗HBVDNA阴转时HBsAg定量为基线值,观察6个月、1年、3年、5年、7年的HBsAg水平的动态变化,并比较HBeAg阳性组及HBeAg阴性组HBsAg定量之间的差异。结果:109例HBeAg阳性病人,HBVDNA阴转时及6个月、1年、3年、5年、7年后HBsAg平均水平分别为3.347、3.329、3.107、3.169、2.960、2.164log10IU/mL;116例HBeAg阴性病人,HBsAg平均水平分别为3.133、3.193、2.970、2.967、2.536、2.083log10IU/mL。经NAs治疗,HBeAg阳性病人和HBeAg阴性病人HBVDNA阴转后、6个月、1年、3年、5年、7年HBsAg水平呈波动性下降趋势(P<0.01)。根据HBsAg定量的下降趋势拟合的线性回归方程,推算HBeAg阳性组和HBeAg阴性组的HBsAg清除时间分别为25年和22年。结论:NAs治疗的CHB病人,理论上推测HBeAg阳性组和HBeAg阴性组HBsAg的清除均需20年以上的时间,采用NAs治疗CHB需要较长的疗程。 Objective:To observe the dynamic change of HBsAg serum level in chronic hepatitis B(CHB) patients treated with NAs for HBVDNA negative conversion,compare the change of HBsAg between HBeAg-positive and HBeAg-negative patients,estimate the time of HBsAg clearance,and explore the possible course of CHB treated with NAs.Methods:The quantitation of HBsAg in patients treated with NA HBVDNA negative conversion was set as the baseline value,the dynamic change of HBsAg levels were observed after 6 months,1 year,3 years,5 years and 7 years of HBVDNA negative conversion,and the difference of HBsAg quantification between HBeAg(+) group and HBeAg(-) group was compared.Results:Among 109 HBeAg-positive patients,the mean levels of HBsAg after 6 months,1 year,3 years,5 years and 7 years of HBVDNA negative conversion were 3.347,3.329,3.107,3.169,2.960 and 2.164 log10IU/mL,respectively.Among 116 HBeAg-negative patients,the mean levels of HBsAg after 6 months,1 year,3 years,5 years and 7 years of HBVDNA negative conversion were 3.133,3.193,2.970,2.967,2.536 and 2.083 log10IU/mL,respectively.After NAs treatment,the HBsAg levels in HBeAg-positive and HBeAg-negative patients showed a decreasing trend of fluctuation at 6 months,1 year,3 years,5 years and 7 years after HBVDNA negative conversion(P<0.01).According to the linear regression equation fitted by the quantitative decline trend of HBsAg,the HBsAg clearance time in HBeAg positive group and HBeAg negative group were calculated to be 25 years and 22 years,respectively.Conclusions:Among the CHB treated with NAs,the clearance time of HBsAg in HBeAg positive group and HBeAg negative group will take more than 20 years in theory.Therefore,the treatment of CHB with NAs requires a long course of treatment.
作者 范新星 崔甫朦 王福生 赵守松 FAN Xin-xing;CUI Fu- meng;WANG Fu-Sheng;ZHAO Shou-song(Department of Infectious Diseases,The First Affiliated Hospital of Bengbu Medical College,Bengbu Anhui 233004;The Fifth Medical Center, The People's Liberation Army General Hospital,Beijing 100039,China)
出处 《蚌埠医学院学报》 CAS 2019年第5期582-584,589,共4页 Journal of Bengbu Medical College
关键词 乙型肝炎 HBSAG NAS HBVDNA hepatitis B HBsAg NAs HBV DNA
  • 相关文献

参考文献7

二级参考文献63

  • 1赵克开,缪晓辉,徐文胜.HepG2.2.15细胞内乙型肝炎病毒cccDNA的定量检测[J].中华传染病杂志,2005,23(1):6-9. 被引量:23
  • 2慢性乙型肝炎防治指南[J].临床肝胆病杂志,2006,22(1):3-15. 被引量:69
  • 3Lai CL,Shouval D,Lok AS,陈楠(摘译),张占卿(审校).恩替卡韦与拉米夫定治疗HBeAg阴性慢性乙型肝炎的对照研究[J].世界感染杂志,2006,6(4):396-396. 被引量:201
  • 4Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis andhepatocellular carcinoma[J]. J Hepatol,2007,46(1):45 52.
  • 5Locarnini S, Zoulim F. Molecular genetics of HBV infection [J]. Antivir Ther, 2010, 15(13) :3 -14.
  • 6Moucari R, Marcetlin P. HBsAg seroclearance: prognostic val- ue for the response to treatment and the long -term outcome [J]. Gastroenterol Clin Biol, 2010, 34(2) : S119 -125.
  • 7Quasdorff M, Protzer U. Control of hepatitis B virus at the level of transcription[J]. J Viral Hepat, 2010, 17(8) : 527 -536.
  • 8Danri M, Burda MR, Will H, et al. Increased hepatocyte turn- over and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circu- lar DNA[J]. Hepatology, 2000, 32(1 ) : 139 -146.
  • 9Delmas J, Schorr O, Jamard C, et al. Inhibitory effect of adefo- vir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus -infected hepatocytes in vivo and in vitro[ J ]. Antimicrob Agents Chemother, 2002, 46 (2) : 425 -433.
  • 10Werle -Lapostolle B, Bowden S, Locarnini S, et al. Persist- ence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy[ J ]. Gastroen- terology, 2004, 126(7) : 1750 -1758.

共引文献1148

同被引文献21

引证文献2

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部